Last month, Jamie Margolis, PhD, who has been with Be The Match BioTherapies® since its inception, was promoted to Director of Product Development Operations. We spoke with her about key challenges the cell therapy industry is facing and how Be The Match BioTherapies is positioned, and growing, to help companies advance their cell or gene…
You’ve recently joined Be The Match BioTherapies full time after two years as a consultant. What is most exciting to you about your new position? We are on the cusp of a major sea change in the way we treat disease, and in the way new therapies are produced and distributed. I am thrilled to…
Access on-demand webinar > One overarching theme throughout all of the conferences we’ve attended this year has been inopportune weather. From the heavy snowfall in Atlanta, Ga., to a snowstorm in Salt Lake City, Utah, to the threat of a major Nor’easter just this past month in Boston, we seemed to bring snow wherever we…
Earlier this month, Dr. Steven Devine, a renowned blood and marrow transplant physician, joined our organization as the Be The Match BioTherapies Medical Director. He came to the organization from the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James). We spoke with Dr. Devine…
As Be The Match BioTherapies enters its third year, could you share what you see as some of the organization’s biggest achievements? There are three major achievements that I’d like to highlight. First, we are proud to be partnering with some truly innovative companies in the cell therapy space to help bring life-saving therapies to…
Cell therapy companies large and small face challenges in securing the raw materials they need for their research and therapy production. That was the message delivered by industry veteran Amy Hines, director of Collection Network Management, Be The Match BioTherapies, at this year’s Cell & Gene Therapy World, hosted by Phacilitate last month in Miami.…
In November, the FDA released its long-awaited regenerative medicine policy framework consisting of four guidance documents; two final and two draft. The guidance documents arrive at a time of rapid growth and expansion in the commercialization of regenerative medicines and represent the FDA’s attempt to ensure safety and effectiveness of the therapies, while spurring innovation…
One of the biggest hurdles in commercializing cell therapies is not the regulatory process, nor is it marketing a brand new, first-in-class product. Instead, many feel that the biggest challenge facing companies developing cell and gene therapies is proving to be the manufacturing process. Manufacturing CAR-T therapies presents multiple unique challenges. First, developing a personalized…
For years, umbilical cord blood (UCB) transplant was considered an acceptable alternative unrelated donor graft for the treatment of leukemia including reconstituting a patient’s immune system. Typically UCB transplants could be performed without the worry of precise patient-donor HLA-compatibility. To date, more than 35,000 cord blood transplants have been conducted worldwide. As use of the…